AU2007277226A1 - A novel lactic acid formulation of MK-0457 useful for the treatment of cancer - Google Patents

A novel lactic acid formulation of MK-0457 useful for the treatment of cancer Download PDF

Info

Publication number
AU2007277226A1
AU2007277226A1 AU2007277226A AU2007277226A AU2007277226A1 AU 2007277226 A1 AU2007277226 A1 AU 2007277226A1 AU 2007277226 A AU2007277226 A AU 2007277226A AU 2007277226 A AU2007277226 A AU 2007277226A AU 2007277226 A1 AU2007277226 A1 AU 2007277226A1
Authority
AU
Australia
Prior art keywords
formulation
inhibitors
lactic acid
agents
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007277226A
Other languages
English (en)
Inventor
David C. Dubost
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU2007277226A1 publication Critical patent/AU2007277226A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2007277226A 2006-07-26 2007-07-24 A novel lactic acid formulation of MK-0457 useful for the treatment of cancer Abandoned AU2007277226A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83344206P 2006-07-26 2006-07-26
US60/833,442 2006-07-26
PCT/US2007/016637 WO2008013807A2 (en) 2006-07-26 2007-07-24 A novel lactic acid formulation of mk-0457 useful for the treatment of cancer

Publications (1)

Publication Number Publication Date
AU2007277226A1 true AU2007277226A1 (en) 2008-01-31

Family

ID=38863098

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007277226A Abandoned AU2007277226A1 (en) 2006-07-26 2007-07-24 A novel lactic acid formulation of MK-0457 useful for the treatment of cancer

Country Status (6)

Country Link
EP (1) EP2051737A2 (zh)
JP (1) JP2009544705A (zh)
CN (1) CN101500613A (zh)
AU (1) AU2007277226A1 (zh)
CA (1) CA2658436A1 (zh)
WO (1) WO2008013807A2 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016247858B2 (en) * 2015-04-17 2020-10-15 Ludwig Institute For Cancer Research Ltd. PLK4 inhibitors
JP6591036B2 (ja) 2016-02-26 2019-10-16 公益財団法人がん研究会 Ｈｐ１の機能に着目した抗癌剤のスクリーニング方法及び評価系

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2616517A1 (en) * 2005-07-26 2007-02-01 Vertex Pharmaceuticals Incorporated Abl kinase inhibition
WO2007136615A2 (en) * 2006-05-16 2007-11-29 Merck & Co., Inc. Combination cancer therapy

Also Published As

Publication number Publication date
WO2008013807A3 (en) 2008-04-03
EP2051737A2 (en) 2009-04-29
CN101500613A (zh) 2009-08-05
WO2008013807A9 (en) 2009-03-12
WO2008013807A2 (en) 2008-01-31
JP2009544705A (ja) 2009-12-17
CA2658436A1 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
US20090227598A1 (en) Ret Tyrosine Kinase Inhibition
EP2755482B1 (en) Combination of mk-1775 and mk-8776 for treating cancer
EP2900241B1 (en) Novel compounds that are erk inhibitors
US9226922B2 (en) Compounds that are ERK inhibitors
US20140349968A1 (en) Compositions and Methods for Treating Cancer
US20210309687A1 (en) Prmt5 inhibitors
EP1885349B1 (en) Sulphamides for treatment of cancer
US20090215775A1 (en) Sulphonamido-Substituted Cyclohexyl Sulphones for Treatment of Cancer
US20090105270A1 (en) Kinase inhibition and anticancer therapy
US11981701B2 (en) PRMT5 inhibitors
US8362075B2 (en) Cyclohexyl sulphones for treatment of cancer
AU2007277226A1 (en) A novel lactic acid formulation of MK-0457 useful for the treatment of cancer
US9546168B2 (en) ERK inhibitors
US20100324063A1 (en) Jak2 tyrosine kinase inhibition
WO2015095250A1 (en) Combination cancer therapy of wee1 and mtor inhibitors
US20090306058A1 (en) Sulphone Derivatives for Treatment of Cancer

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period